News Website

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen - Business Wire

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen Business Wire

Published: Oct. 18, 2025, 10 a.m.

Read Full Article

Study Explores Impact of Uterine Adenomyosis on Survival Outcomes in Non-Endometrioid Endometrial Cancer - geneonline.com

Study Explores Impact of Uterine Adenomyosis on Survival Outcomes in Non-Endometrioid Endometrial Cancer geneonline.com

Published: Oct. 14, 2025, 6:39 p.m.

Read Full Article

Uterine Adenomyosis Influences Non-Endometrioid Cancer Survival - Bioengineer.org

Uterine Adenomyosis Influences Non-Endometrioid Cancer Survival Bioengineer.org

Published: Oct. 14, 2025, 5:14 p.m.

Read Full Article

Uterine Adenomyosis Influences Non-Endometrioid Cancer Survival - BIOENGINEER.ORG

Uterine Adenomyosis Influences Non-Endometrioid Cancer Survival BIOENGINEER.ORG

Published: Oct. 14, 2025, 5:14 p.m.

Read Full Article

Uterine Adenomyosis Influences Non-Endometrioid Cancer Survival - bioengineer.org

Uterine Adenomyosis Influences Non-Endometrioid Cancer Survival bioengineer.org

Published: Oct. 14, 2025, 5:14 p.m.

Read Full Article

Immunotherapy Plus Chemotherapy Boosts Endometrial Cancer Survival - Bioengineer.org

Immunotherapy Plus Chemotherapy Boosts Endometrial Cancer Survival Bioengineer.org

Published: Oct. 14, 2025, 4:49 p.m.

Read Full Article

Immunotherapy Plus Chemotherapy Boosts Endometrial Cancer Survival - BIOENGINEER.ORG

Immunotherapy Plus Chemotherapy Boosts Endometrial Cancer Survival BIOENGINEER.ORG

Published: Oct. 14, 2025, 4:49 p.m.

Read Full Article

Adjuvant Chemotherapy Improves Long-Term Survival in Endometrial Cancer - CancerNetwork

Adjuvant Chemotherapy Improves Long-Term Survival in Endometrial Cancer CancerNetwork

Published: Oct. 13, 2025, 10:05 p.m.

Read Full Article

Researchers awarded $11.2M grant to close endometrial cancer survival gap - UNC Gillings School of Global Public Health

Researchers awarded $11.2M grant to close endometrial cancer survival gap UNC Gillings School of Global Public Health

Published: Oct. 9, 2025, 4:10 p.m.

Read Full Article

TGFB1/SMAD3-Driven Macrophage-Myofibroblast Transition Promotes Fibrosis Progression in Endometriosis.

Endometriosis is a chronic gynecological disorder characterized by progressive fibrosis, which is closely associated with clinical symptoms such as dysmenorrhea and infertility. While myofibroblast activation is central to fibrogenesis, the …

Published: Oct. 7, 2025, midnight

Read Full Article

SMAD3 TGFB1 endometriosis extracellular matrix deposition fibrosis macrophage–myofibroblast transition

Latest Articles

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen - Business Wire

Study Explores Impact of Uterine Adenomyosis on Survival Outcomes in Non-Endometrioid Endometrial Cancer - geneonline.com

Uterine Adenomyosis Influences Non-Endometrioid Cancer Survival - Bioengineer.org

Uterine Adenomyosis Influences Non-Endometrioid Cancer Survival - BIOENGINEER.ORG

Uterine Adenomyosis Influences Non-Endometrioid Cancer Survival - bioengineer.org

Immunotherapy Plus Chemotherapy Boosts Endometrial Cancer Survival - Bioengineer.org

Immunotherapy Plus Chemotherapy Boosts Endometrial Cancer Survival - BIOENGINEER.ORG

Adjuvant Chemotherapy Improves Long-Term Survival in Endometrial Cancer - CancerNetwork

Researchers awarded $11.2M grant to close endometrial cancer survival gap - UNC Gillings School of Global Public Health

TGFB1/SMAD3-Driven Macrophage-Myofibroblast Transition Promotes Fibrosis Progression in Endometriosis.

Subscribe to Our Newsletter